RUNX2-modifying enzymes: therapeutic targets for bone diseases

被引:59
|
作者
Kim, Woo-Jin [1 ]
Shin, Hye-Lim [1 ]
Kim, Bong-Soo [1 ]
Kim, Hyun-Jung [1 ]
Ryoo, Hyun-Mo [1 ]
机构
[1] Seoul Natl Univ, Basic Res Lab Epigenet Regenerat Aged Skeletomusc, Dept Mol Genet & Dent Pharmacol, Sch Dent,Dent Res Inst, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
FIBROBLAST-GROWTH-FACTOR; PROLYL-ISOMERASE PIN1; OSTEOBLAST DIFFERENTIATION; SIGNALING PATHWAYS; RUNX2; EXPRESSION; PREVENTS; PHOSPHORYLATION; INHIBITOR; FGFR2;
D O I
10.1038/s12276-020-0471-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
RUNX2 is a master transcription factor of osteoblast differentiation. RUNX2 expression in the bone and osteogenic front of a suture is crucial for cranial suture closure and membranous bone morphogenesis. In this manner, the regulation of RUNX2 is precisely controlled by multiple posttranslational modifications (PTMs) mediated by the stepwise recruitment of multiple enzymes. Genetic defects inRUNX2itself or in its PTM regulatory pathways result in craniofacial malformations. Haploinsufficiency in RUNX2 causes cleidocranial dysplasia (CCD), which is characterized by open fontanelle and hypoplastic clavicles. In contrast, gain-of-function mutations in FGFRs, which are known upstream stimulating signals of RUNX2 activity, cause craniosynostosis (CS) characterized by premature suture obliteration. The identification of these PTM cascades could suggest suitable drug targets for RUNX2 regulation. In this review, we will focus on the mechanism of RUNX2 regulation mediated by PTMs, such as phosphorylation, prolyl isomerization, acetylation, and ubiquitination, and we will summarize the therapeutics associated with each PTM enzyme for the treatment of congenital cranial suture anomalies. Regenerative medicine: Manipulating modifications that control bone-building Therapies that modulate the activity of the regulatory protein RUNX2 could potentially restore normal bone development in a range of skeletal disorders, and repair damage from injury or degeneration. RUNX2 is an essential regulator of genes that drive formation of bone-producing osteoblast cells. It can be activated or inactivated by the enzymatic addition of various chemical groups. Hyun-Mo Ryoo and colleagues at Seoul National University, South Korea, review the role of such modifications in bone disorders. For example, the loss of modifications activated by RUNX2 can result in delayed integration of the bones that form the skull. The authors highlight potential opportunities to manipulate these modification processes to treat this and other developmental disorders. Similar strategies could also promote repair of fractures or counter osteoporotic bone loss.
引用
收藏
页码:1178 / 1184
页数:7
相关论文
共 50 条
  • [1] tRNA Modifications and Modifying Enzymes in Disease, the Potential Therapeutic Targets
    Cui, Weifang
    Zhao, Deze
    Jiang, Junjie
    Tang, Faqing
    Zhang, Chunfang
    Duan, Chaojun
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2023, 19 (04): : 1146 - 1162
  • [2] Runx2 and microRNA regulation in bone and cartilage diseases
    Zhao, Weiwei
    Zhang, Shanxing
    Wang, Baoli
    Huang, Jian
    Lu, William W.
    Chen, Di
    MUSCULOSKELETAL REPAIR AND REGENERATION, 2016, 1383 : 80 - 87
  • [3] Circadian clock genes as promising therapeutic targets for bone loss
    Qin, Yi
    Chen, Zhong-hua
    Wu, Jun-Jie
    Zhang, Zhen-Yu
    Yuan, Zheng-Dong
    Guo, Dan-Yang
    Chen, Meng-Nan
    Li, Xia
    Yuan, Feng-Lai
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 157
  • [4] Histone Methyltransferases as Therapeutic Targets for Kidney Diseases
    Yu, Chao
    Zhuang, Shougang
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [5] Runx2 and Polycystins in Bone Mechanotransduction: Challenges for Therapeutic Opportunities
    Gargalionis, Antonios N.
    Adamopoulos, Christos
    Vottis, Christos T.
    Papavassiliou, Athanasios G.
    Basdra, Efthimia K.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (10)
  • [6] Deubiquitinating Enzymes as Therapeutic Targets in Cancer
    Lim, Key-Hwan
    Baek, Kwang-Hyun
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (22) : 4039 - 4052
  • [7] New targets for disease modifying osteoarthritis drugs: chondrogenesis and Runx1
    Blanco, Francisco J.
    Ruiz-Romero, Cristina
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (05) : 631 - 634
  • [8] Chromatin regulation in schistosomes and histone modifying enzymes as drug targets
    Pierce, Raymond John
    Dubois-Abdesselem, Florence
    Caby, Stephanie
    Trolet, Jacques
    Lancelot, Julien
    Oger, Frederik
    Bertheaume, Nicolas
    Roger, Emmanuel
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2011, 106 (07): : 794 - 801
  • [9] The "bone morphogenic proteins" pathways in bone and joint diseases: Translational perspectives from physiopathology to therapeutic targets
    Biver, Emmanuel
    Hardouin, Pierre
    Caverzasio, Joseph
    CYTOKINE & GROWTH FACTOR REVIEWS, 2013, 24 (01) : 69 - 81
  • [10] Molecular Signaling Pathways and Essential Metabolic Elements in Bone Remodeling: An Implication of Therapeutic Targets for Bone Diseases
    Sharma, Aditi
    Sharma, Lalit
    Goyal, Rohit
    CURRENT DRUG TARGETS, 2021, 22 (01) : 77 - 104